Symbol search
date o news sym
globenewswire
11:30 Tue 4
Nws
SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX
- Important for Patients Who Cannot Swallow Oral Capsules - - Important for Patients Who Cannot Swallow Oral Capsules -
https://www.globenewswire.com/news-release/2021/05/04/2222157/9738/en/SIGA-Announces-New-Drug-Application-Filing-with-FDA-for-Intravenous-Formulation-of-TPOXX.html
SIGA
Healt
Text search
date o news
globenewswire
11:30 Tue 4
Nws
SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX
- Important for Patients Who Cannot Swallow Oral Capsules - - Important for Patients Who Cannot Swallow Oral Capsules -
SIGA
Healt
prnewswire:443
11:30 Wed 5
Nws
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO (ivosidenib tablets) in IDH1-mutated Cholangiocarcinoma
BOSTON, May 5, 2021 /PRNewswire/ -- Servier Pharmaceuticals, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application...
AGIO
Healt
prnewswire:443
01:30 Mon 3
Nws
Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor
BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced the U.S. Food and Drug Administration (FDA) has approved company's Investigational New Drug (IND) application to develop a KRAS G12C inhibitor. IND application to the National...


globenewswire
11:05 Mon 3
Nws
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE for Treatment of Macular Edema Associated with Uveitis
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for XIPERE TM (triamcinolone acetonide suprachoroidal injectable suspension) for the treatment of macular edema associated with uveitis.
CLSD
Healt
globenewswire
00:49 Wed 5
Nws
Supernus Announces Paragraph IV ANDA Filing for XADAGO
ROCKVILLE, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Newron Pharmaceuticals S.p.A. (Newron) received a Paragraph IV Notice Letter (Notice Letter) from Aurobindo Pharma Limited, India and its wholly owned subsidiary Aurobindo Pharma USA Inc. (collectively Aurobindo), advising Newron of the filing by Aurobindo of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval for safinamide tablets. The Notice Letter is directed to the three XADAGO patents with U.S. patent numbers 8,076,515, 8,278,485 and 8,283,380, that expire between June 2027 and December 2028 and are listed in the FDA's publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. The Company has a license agreement with Zambon S.p.A., Newrons partner, related to the XADAGO Patents, and as a new chemical entity, XADAGO is under the 5 year FDA exclusivity period that expires on March 21, 2022. The Company is currently reviewing the details of this Notice Letter with its partners to respond as appropriate to protect the intellectual property rights relating to XADAGO.
SUPN
Healt
globenewswire
20:05 Tue 4
Nws
Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention
Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention


prnewswire:443
13:08 Tue 4
Nws
Clarity receives US FDA clearance of IND Application for its next-generation PSMA theranostic products
SYDNEY, May 4, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has received a response from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug...


feed businesswire
12:17 Wed 5
NwsFnnc
MajorClarity Partners With Common App
RICHMOND, Va.--(BUSINESS WIRE)--'MajorClarity announces partnership with Common App for the 2021-2022 application cycle to streamline application process for K12 schools.'


proactiveinvestors
13:42 Tue 4
Tetra Bio-Pharma to reactivate clinical trial to evaluate veterinary drug PPP-003v to treat indolent corneal ulcers in companion animals
Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) has announced it will reactivate a clinical trial to evaluate the safety, tolerability, and potential efficacy of its veterinary ophthalmic drug PPP-003v as a treatment of indolent corneal ulcers in companion animals.  The companys announcement comes after it received authorization from the Veterinary Drugs Directorate of Health Canada for a one-year extension to continue the clinical trial.  In partnership with a clinical veterinary ophthalmologist team, Tetra said it had initiated a pilot phase clinical trial in domestic dogs as a proof-of-concept for its PPP-003v drug candidate for eye pain. While the completion of enrollment was planned by April 30, 2020, the trial was halted due to COVID-19 measures, which restricted the ability of owners to bring their pets to the veterinary clinic for trial procedures. READ: Tetra Bio-Pharma wins a drug license to distribute REDUVO cannabinoid soft gel capsules in Canada Canine indolent corneal ulcers occur frequently in specific breeds of dogs. Corneal ulcers and non-ulcerative keratitis are among the most common painful eye disorders seen by veterinarians and if left untreated, can result in pain, inflammation, scarring, and vision loss. The company said PPP-003v contains a synthetic cannabinoid 2 receptor-selective agent in an optimized formulation for topical delivery to the eye. Extensive preclinical research has validated the Cannabinoid 2 receptor as a key drug target for reducing ocular inflammation and pain. 'We are pleased with this regulatory authorization and the ability to re-activate the trial, said Tetra CEO Dr Guy Chamberland in a statement. While the active pharmaceutical ingredient used in the PPP-003v drug formulation is the same as the one used in ARDS-003, Tetra's innovative immunomodulator drug concurrently being developed for COVID-19, there is a major difference with how the drug is delivered. PPP-003v is intended to be used as a topical medication and is delivered as a sterile eye drop and ointment, while ARDS-003 is a sterile injectable nano-emulsion finished drug product. Tetra said the study will be the first time a synthetic cannabinoid agent is used clinically in companion animals with the goal of providing pet owners with an alternative ophthalmic medication for pain and inflammatory disease. Based on positive results from this initial proof-of-concept clinical trial, Tetra said it will submit a new clinical trial application to the Veterinary Drugs Directorate of Health Canada to extend the findings of safety and efficacy for PPP003v, as well as commence regulatory filings for a New Animal Drug Application with the US Food and Drug Administration (FDA) to ensure that the drug will be available to the Canadian and US markets for eye pain and inflammation. Dr Chamberland added: 'The PPP-003 program, including PPP-003v, represents a significant opportunity for Tetra since there is a substantial unmet medical need for painful inflammatory eye disease. Tetra's veterinary ocular program is a key component of this program and the ongoing pilot phase trial will provide important data which can potentially be included as part of the pre-clinical data that will be submitted to support PPP-003 use in human clinical trials. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham  
TBPMF
Healt
prnewswire:443
13:08 Tue 4
Nws
Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration
ZUG, Switzerland, May 4, 2021 /PRNewswire/ -- Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, today announces that it has entered into a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug...


feedburner
18:41 Tue 4
NwsFnnc
Cased announces $2.25M seed round to help developers work in production environments
An issue every developer faces is dealing with problems on a live application without messing it up. In fact, in many companies such access is restricted. Cased, an early stage startup, has come up with a solution to provide a way to work safely with the live application. Today, the company announced a $2.25 million […]


globenewswire
10:00 Mon 3
Nws
Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection
RANCHO CUCAMONGA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (FDA) approved the Companys Abbreviated New Drug Application (ANDA) for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia (PCA), only for use with a compatible Alaris infusion device, and for which alternative treatments are inadequate. For the past 30 years, the company has sold and marketed the product under the grandfather exception to the FDAs Prescription Drug Wrap-Up program. Net revenues for the Companys Morphine injection for the year ended December 31, 2020, were $2.3 million.
AMPH
Healt
prnewswire:443
20:15 Tue 4
Nws
Patient-derived Xenograft/PDX Model Market by Type, Tumor Type, Application, End-user - Global Forecast to 2026
DUBLIN, May 4, 2021 /PRNewswire/ -- The 'Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to...


globenewswire
11:30 Tue 4
Nws
Plus Therapeutics Announces Key RNLDevelopment andcGMP Drug Manufacturing Collaboration Agreements
Agreements are a major step for ongoing clinical trials and future commercial drug supply Agreements are a major step for ongoing clinical trials and future commercial drug supply


proactiveinvestors
20:48 Wed 5
TRACON Pharmaceuticals ends 1Q with $30.4M to fund its cancer drug trials
TRACON Pharmaceuticals Inc (NASDAQ:TCON) ended the first quarter of 2021 on March 31 with cash and equivalents of $30.4 million, which it said will fund its operations into the second half of 2022. The company also noted that as of May 5, it has initiated 22 US clinical sites and enrolled more than 20 patients in the pivotal ENVASARC trial of single-agent envafolimab and envafolimab combined with Yervoy, which has triggered the initial Data Monitoring Committee review of safety data from each cohort. We continue to be pleased with the pace of enrollment in the pivotal ENVASARC trial and remain on track to deliver interim data in the second half of this year and final data in 2022, CEO Dr Charles Theuer said in a statement. READ: TRACON Pharmaceuticals driving the development of targeted therapies for cancer via collaborations We have now initiated 22 sites and have enrolled more than 20 patients which has triggered the initial Data Monitoring Committee review of safety data from each cohort, which we expect later this quarter, Dr Theuer added. In April, TRACON resubmitted its Orphan Drug Designation application to the US Food and Drug Administration (FDA) in response to a request for preclinical or clinical evidence of activity for its clinical-stage drug envafolimab for treating sarcoma. It expects correspondence from the FDA this quarter based on the amended application. The company also outlined some other key upcoming milestones, including: Orphan Drug Designation for envafolimab in soft tissue sarcoma from the FDA in 1H 2021 Independent Data Monitoring Committee review of ENVASARC safety data in 1H 2021 American Society of Clinical Oncology (ASCO) presentation of ENVASARC pivotal trial design in 1H 2021 ASCO presentation of TJ004309 Phase 1 data in 1H 2021 Interim ENVASARC efficacy and safety data in 2H 2021 Request FDA breakthrough therapy designation or Fast Track designation for envafolimab in 2H 2021 Decision on the envafolimab New Drug Application (NDA) in MSI-H/dMMR cancer that is under priority review by the Chinese National Medical Products Administration (NMPA) TRACON has positioned itself as a collaboration partner that leads the regulatory filings, clinical trials, as well as US commercialization of best-in-class drug candidates, as an alternative to expensive contract research organization (CRO) based development. Contact Sean at sean@proactiveinvestors.com
TCON
Healt
prnewswire:443
12:39 Wed 5
Nws
Ai2 Announces the Future of Remote Client Monitoring with the Launch of CareMate
RENO, Nev., May 5, 2021 /PRNewswire/ -- Algorithmic Intuition (Ai2) today announces the launch of CareMate remote client monitoring. CareMate is a device, neuronet-supported software, dashboard, and mobile application that come together to create the ultimate client monitoring and...


economictimes indiatimes
6h ago
Nws
Covid drug: Natco eyes patent waiver
Making its case, Natcos application said Olumiant is not manufactured in India less than 9,000 tablets were imported in 2019 and 2020, at an average cost of Rs 3,230 per tablet. Citing the pricing as a significant barrier, it said a 14-day regimen (one tablet a day) works out to approximately Rs 45,220 per patient, which most Indians can ill-afford.


globenewswire
12:30 Tue 4
NwsFnnc
3D Systems Announces Expansion Plans to Address Rising Demand for New Healthcare and Industrial Applications
ROCK HILL, S.C., May 04, 2021 (GLOBE NEWSWIRE) -- 3D Systems (NYSE:DDD) today announced it will increase its presence in Denver, Colorado to support its fast-growing healthcare solutions business, and expand industrial application development capabilities for its Application Innovation Group (AIG). This activity is a continuation of the investment phase of the companys plan to focus on its strategic purpose as the leaders in enabling additive manufacturing solutions for applications in growing markets that demand high-reliability products.


proactiveinvestors
14:45 Mon 3
Tetra Bio-Pharma wins a drug license to distribute REDUVO cannabinoid soft gel capsules in Canada
Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, revealed that it has been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO cannabinoid soft gel capsules in Canada. REDUVO is a synthetic THC-based soft gel capsule aimed as a therapy to combat severe nausea and vomiting associated with cancer chemotherapy. It is currently being assessed by Health Canada for the issuance of a Drug Identification Number (DIN). REDUVO, known as Marinol in the United States, has been approved as a regulated pharmaceutical drug by the US Food and Drug Administration since 1985. READ: Tetra Bio-Pharma advances REDUVO cannabinoid soft gel capsules new drug submission file in Canada 'We look forward to working closely with our Contract Manufacturing Organization for the importation, warehousing, and dissemination of the THC pharmaceutical drug to pharmacies across Canada, Tetra CEO Dr Guy Chamberland said in a statement. We stand by our commitment to launch our THC-based prescription drug to the Canadian market in late 2021,' he added. On April 1, 2021, the company announced it had received a compliant rated GMP inspection by Health Canada. Subsequently, Health Canada finalized their regulatory assessment and determined that Tetra met all the requirements for the issuance of a DEL. In Canada, any company that intends to distribute drugs must obtain a DEL as per Health Canada regulatory requirements. It is a comprehensive and stringent process to obtain a DEL approval as a company must demonstrate it meets strict quality control standards and procedures. In addition, a company that intends to distribute pharmaceutical drugs that contain cannabis must also obtain a Health Canada Cannabis Drug License (CDL). Only companies, such as Tetra Bio-Pharma with a Health Canada issued DEL are eligible to apply for a CDL. Tetra said that it has submitted the CDL application to Health Canada. Contact the author Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive  
TBPMF
Healt
proactiveinvestors
16:45 Wed 5
Mountain Valley MD says it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials
Mountain Valley MD Holdings Inc. (CSE:MVMD) (FRA:20MP) (OTCQB:MVMDF) announced that it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma. Mountain Valley MD said the cancer patent has been filed for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens. The company noted that it is proceeding with three separate pre-clinical trials with specialized third-party cancer CROs: (1) triple-negative breast cancer; (2) metastatic melanoma; and (3) Lewis Lung Carcinoma as a proxy for non-small cell lung carcinoma. READ: Mountain Valley MD proceeds with pre-clinical cancer trials and files a related cancer patent Mountain Valley MD said it believes the research will have near-immediate application to direct human trials based on safety and efficacy of ivermectin. 'The extensive research supporting the drug ivermectin as effective in the inhibition of proliferation, metastasis, and angiogenic activity in a variety of cancers, and as an initiator of immunogenic cell death, is overwhelming,' stated Mike Farber, director of Life Sciences at Mountain Valley MD.  'Imagine what is possible when you have the world's only human injectable form of ivermectin that can be directly injected into a tumor or provided through more bio-available forms such as intravenously.  We believe this will be groundbreaking research with near-immediate application to be able to proceed directly to human trials based on the safety and efficacy of ivermectin,' Farber added. Extensive researching Leading up to the implementation of pre-clinical trial cancer research, Mountain Valley MD said it has been extensively researching the drug ivermectin, including its impact on cancer, and has included numerous abstracts at the end of this media release.   All of the research articles cited involve either existing oral ivermectin in a murine model or the in-vitro testing of ivermectin utilizing organic solvents for solubilization that would be prohibited in a human intravenous or intratumoral administration. As cited by Pharmacological Research in January 2021, Ivermectin has powerful antitumor effects in a variety of cancer cells and promotes programmed cancer cell death, including apoptosis, autophagy, and necrosis.  The research also identifies how ivermectin has been shown to inhibit tumor stem cells and reverse multidrug resistance, Mountain Valley MD added. Mountain Valley MD filed its cancer adjuvant patent, Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies for its solubilized ivermectin (Ivectosol). The patent-pending adjuvant utilizes the company's advances in macrocyclic lactone solubility to consider Ivectosol as a viable adjuvant for numerous cancer therapies.   The company's solubility technology applied to the ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection or intravenous infusion.  'Ivermectin is a Nobel prize-winning global blockbuster drug with unprecedented potential.  Overcoming its number one limitation of solubility using FDA-approved excipients has opened up significant applications across multiple human and animal health lanes for Mountain Valley MD and our partners,' said Dennis Hancock, president and CEO of Mountain Valley MD.  'Driving innovation in cancer research to support positive outcomes for increased survival rates, productivity, and improved quality of life for the global population is directly aligned with our mission of more life, less death.  We couldn't be more honoured to drive forward this important work,' he added. The three pre-clinical trials that are being conducted are designed to prove the utility of Ivectosol to synergize and improve various cancer regimens currently in use and as a potent enhancer of current immunotherapies and chemotherapies for difficult to treat cancers. Study One:  Triple-negative breast cancer Study will test the effectiveness of Ivectosol combined with checkpoint inhibitor that would be equivalent to either OPDIVO or Keytruda for disease progression and complete response rate Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor and intratumoral IVM + checkpoint inhibitor Estimated initial readouts/analysis 2nd week of June, 2021 Complete readout with flow cytometry and statistical evaluation estimated mid-July, 2021 with possible abstract submission in August, 2021 Study Two:  Metastatic melanoma Study will test the effectiveness of Ivectosol intratumoral combined with checkpoint inhibitor for disease progression and complete response rate Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor and intratumoral IVM + checkpoint inhibitor Estimated initial readouts by end of June, 2021 Complete readout with flow cytometry and statistical evaluations estimated end of July, 2021 with possible abstract submission in August, 2021 Study Three:  Lewis lung carcinoma as a proxy for non-small cell lung carcinoma Study will test the effectiveness of Ivectosol intratumorally combined with checkpoint inhibitor for disease progression and complete response rate Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor, intratumoral IVM + checkpoint inhibitor, navalbine + intratumoral IVM Estimated initial readouts by end of June, 2021 Complete readouts with flow cytometry and statistical evaluation estimated by end of July, 2021 with possible abstract submission in August, 2021 All three studies will assess tumor growth and metastases through bioluminescence imaging, a non-invasive optical imaging modality designed to visualize and quantify bioluminescent signal in tissues.   The company is also actively pursuing a pre-clinical trial for bladder cancer and is currently assessing the best option to proceed through the evaluation of CRO proposals. Mountain Valley MD is building a world-class biotech and life sciences company organization centred around the implementation of its patented Quicksome oral drug formulation and delivery technologies and its Quicksol solubilization technology for macrocyclic lactones, to innovate industry-leading products that are sought out globally. Contact the author at jon.hopkins@proactiveinvestors.com


marketwatch
12:11 Wed 5
Nws
: Pfizers next play: A vaccine maker and pandemic partner to governments
Pfizer Inc.s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug makers top-selling drug and forging a new path into infectious diseases for the legacy drug maker.


SEC
06:06 Wed 5
Nws
8-K MEDICINOVA INC (0001226616) (Filer)
FORM 8-K Item8.01 Other Events. MediciNova, Inc. announced today the appointment of Dr.Federico Gaeta as Chief Scientific Officer. Dr.Gaeta has served as Senior Scientific Advisor and previously as Consultant for MediciNova since 2010, and is responsible for drug discovery, formulation development, manufacturing and related activities. Previously, Dr.Gaeta was a consultant for Avigen, Inc. before its merger with MediciNova. Prior to joining forces with MediciNova, Dr.Gaeta was a senior management executive with Geron and Cytel corporations. In addition, Dr.Gaeta garnered additional drug discovery and development experience at multinational pharma companies including Bristol Myers Squibb and Merck. Dr.Gaeta obtained his Ph.D. in chemistry from Rice University and completed postdoctoral research at UCLA under Dr.DonaldJ. Cram, Nobel laureate in chemistry. He is named inventor in over 100 patents and patent publications. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MNOV

globenewswire
11:30 Mon 3
Nws
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA (lumateperone) sNDAs for the Treatment of Bipolar Depression
NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Applications (sNDAs) for lumateperone, an investigational agent for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 17, 2021 for the applications. If approved, CAPLYTA has the potential to be an important medicine for a broad group of patients suffering from these highly prevalent, chronic complex conditions.
ITCI
Healt
prnewswire:443
15:15 Tue 4
Nws
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
LOS ANGELES, May 4, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acadia Pharmaceuticals Inc. ('Acadia' or the 'Company') (NASDAQ: ACAD) securities between...
ACAD
Healt
prnewswire:443
5h ago
Nws
Pomerantz Law Firm Announces the Filing of a Class Action Against LifeMD, Inc. f/k/a Conversion Labs, Inc. and Certain Officers - LFMD
NEW YORK, May 5, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs, Inc. ('LifeMD' or the 'Company') (NASDAQ: LFMD) and certain of its officers. The class action, filed in the United States District Court for...
CVLB
Healt
bbci co uk
23:49 Sun 2
Nws
Apetamin: Instagram criticised over weight gain drug
NHS England calls for a clamp down on the targeting of the 'dangerous' unlicensed drug at young women.


prnewswire:443
01:16 Tue 4
Nws
Delay in Filing Annual Financial Statements
TORONTO, May 3, 2021 /PRNewswire/ - XTM, Inc. ('XTM' or the 'Company') (CSE: PAID) (QB: XTMIF), (FSE: 7XT) announces that it did not file its annual audited financial statements, management's discussion and analysis and related certifications for the fiscal year ending December 31, 2020...


news google
13:17 Wed 5
Nws
EXCLUSIVE Lilly hit by staff accusations, FDA scrutiny at COVID drug factories - Reuters
EXCLUSIVE Lilly hit by staff accusations, FDA scrutiny at COVID drug factories    Reuters Lilly announces global donations of COVID treatments    WISHTV.com New Investor? Buy These 2 Rock-Solid Stalwarts for Safety and Dividends    Motley Fool Eli Lilly to supply 400000 tablets of its COVID-19 treatment to India    Reuters Eli Lilly India chief says company in talks with generic firms here on royalty free voluntary licensing of...    Moneycontrol.com View Full Coverage on Google News
LLY
Healt
prnewswire:443
10:30 Mon 3
NwsFnnc
Newater Technology, Inc. Announces Year 2020 Audited Financial Results
NEW YORK, May 3, 2021 /PRNewswire/ -- Newater Technology, Inc. (NASDAQ: NEWA) (''NEWA,'' ''we,'' ''our'' or the ''Company''), a leading company specializing in development, production and application of DTRO equipment and systems used in waste water filtration, today announced its...
NEWA
Indus
prnewswire:443
8h ago
Nws
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
SHANGHAI, May 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Greater China and other parts of Asia, announced today that the Ministry of Food and Drug Safety (MFDS)...
IMMU
Healt